ReNeuron announced at the AAO 2019 meeting positive clinical data for its Phase 1/2a clinical trial of hRPC stem cell therapy for retinitis pigmentosa.
The ongoing trial is an open-label study to evaluate the safety, tolerability, and efficacy of hRPC stem cell therapy in patients with advanced retinitis pigmentosa. Twenty-two patients have been treated (12 in Phase 1 and 10 in Phase 2a). Further long-term follow-up data will be collected.
The trial so far has shown good overall safety; no immune or cell-related adverse events were reported. One of the benefits of the hRPC stem cell therapy is its ability to be delivered directly into the subretinal space.
Benjamin R. Yerxa PhD, Chief Executive Officer of the US-based non-profit organization Foundation Fighting Blindness, noted, “…Any gain in vision, or even stabilization, is a major step forward for patients with retinitis pigmentosa as currently it is a condition where progressive loss of vision leads to blindness.”
You can read more here.